A5054350428- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Graphene and Nanomaterials Applications
- Cytokine Signaling Pathways and Interactions
- Atherosclerosis and Cardiovascular Diseases
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- HIV-related health complications and treatments
- interferon and immune responses
- Peptidase Inhibition and Analysis
- Systemic Lupus Erythematosus Research
Yale University
2025
University of Chicago
2022-2024
Long-circulating nanomedicines efficiently deliver chemotherapies to tumors reduce general toxicity. However, extended blood circulation of can increase drug exposure leukocytes and lead hematological Here, we report a two-stage release strategy enhance the deposition antitumor efficacy OxPt/SN38 core–shell nanoparticles with hydrophilic oxaliplatin (OxPt) prodrug coordination polymer core lipid shell containing hydrophobic cholesterol-conjugated SN38 (Chol-SN38). By conjugating cholesterol...
The low success rate of cancer nanomedicines has raised debate on the role enhanced permeability and retention (EPR) effect tumor deposition nanotherapeutics. Here, we report a bifunctional nanoscale coordination polymer (NCP), oxaliplatin (OX)/2′,3′-cyclic guanosine monophosphate–adenosine monophosphate (GA), to overcome EPR limitation through stimulator interferon genes (STING) activation enhance chemotherapeutic STING agonist delivery for eradication. OX/GA encapsulates GA OX in NCP...
The binding of plasma proteins to nanomedicines is widely considered detrimental their delivery tumors. Here, the design OxPt/SN38 nanoparticle containing a hydrophilic oxaliplatin (OxPt) prodrug in coordination polymer core and hydrophobic cholesterol-conjugated SN38 on lipid shell for active tumor targeting reported. hitchhikes low-density lipoprotein (LDL) particles, concentrates tumors via LDL receptor-mediated endocytosis, selectively releases OxPt acidic, esterase-rich, reducing...
Abstract The addition of immune checkpoint blockade to standard chemotherapy has changed the standards care for some cancer patients. However, current chemo‐immunotherapy strategies do not benefit most colorectal patients and many triple‐negative breast Here, design a three‐in‐one nanoscale coordination polymer (NCP), OX/GC/CQ, comprising prodrugs oxaliplatin (OX), gemcitabine (GC), 5‐carboxy‐8‐hydroxyquinoline (CQ) triple‐modality is reported. OX/GC/CQ exhibits optimal pharmacokinetics...